Thanks, Bilal. Good morning, everyone. As Bilal mentioned, we posted net investment income of $0.42 per share for the first quarter once again covering our $0.34 per share distribution declared during the quarter. Our current distribution rate represents a 13.7% annualized yield based on the price of our common stock at quarter end. We also announced that our quarterly distribution for the second quarter will remain at $0.34 per share. Our net asset value per share decreased by approximately $1 to $11.08. As Bilal mentioned, this decline was primarily due to unrealized depreciation concentrated in a couple of positions, most notably our equity position in Pfanstiehl Holdings, which declined $7.9 million or $0.59 per share. Pfanstiehl is a manufacturer of specialized products for leading biopharmaceutical firms. We believe its recent decline in value is due to a cyclical downturn in the life sciences industry. However, we remain positive about the long-term outlook for the business. This is a position we invested in more than 10 years ago at a modest cost of only $200,000. To date, we have received approximately $3.4 million in distributions or approximately 17x our cost and as of quarter end, our fair value is $63.1 million. As you know, we have experience in making these kind of selective equity investments alongside certain of our initial debt investments. This quarter, we had another equity realization in TRS Services for gross proceeds of $3.9 million, recognizing a realized gain of $1.4 million. In addition, we recognized $1.9 million of accumulated preferred dividends from this investment during the quarter. As mentioned, we placed on borrower on nonaccrual status during the quarter. SSJA Bariatric, a provider of bariatric surgery and weight management solutions. The sponsor as well as the founder and CEO, have recently contributed meaningful additional capital into the company which, in our view, demonstrates their commitment to the business. This loan had a fair value of approximately $8.8 million as of March 31, representing approximately 2% of the portfolio. Overall, 4.8% of our investments at fair value were on nonaccrual status at quarter's end. Turning to the income statement. Total investment income was up by approximately 6% to $14.2 million compared to the prior quarter. This was largely due to a nonrecurring increase in dividend income which includes the TRS dividends I just mentioned, offset by a decline in interest income partly due to a smaller overall investment portfolio. This lower overall investment balance is partly related to certain larger prepayments we received in the fourth quarter of 2023, which we utilized to redeem our remaining $31.9 million of SBIC debentures. On March 1, we completed this redemption which I previously mentioned was our plan on our prior call. Total expenses of $8.6 million were down approximately 1.7% during the period primarily due to a decrease in interest expense related to lower average outstanding debt balances during the quarter. As I mentioned, net investment income was $0.42 per share for the first quarter. Net investment income covered our $0.34 distribution for the first quarter, and we believe that net investment income has benefited from our balance sheet positioning, given that 91% of our loan portfolio at fair value is floating rate while approximately 70% of our outstanding debt is fixed rate. It is also worth noting that at quarter end, all of our outstanding debt matures in 2026 or later and approximately 70% of our outstanding debt was unsecured. While we have been actively paying down debt over the past few quarters, we have experienced a decline in our regulatory asset coverage ratio due to the unrealized depreciation concentrated in a few positions. In the last quarter, we paid down $43.9 million of debt, including the SBIC debt I mentioned earlier. However, while the SBIC debt contributed to an overall reduction in the balance sheet leverage, this debt was not a component of our regulatory asset coverage requirement. As of quarter end, our debt-to-equity ratio was approximately 1.74x, and our regulatory asset coverage ratio was 157%. Turning to our investments. We believe the overall performance of our portfolio companies remains solid in this uncertain macroeconomic environment. We are committed to being senior in the capital structure and selective in our underwriting. We remained cautious about new originations and continue to see slow M&A activity during the first quarter. We continue to support our portfolio companies as they identify add-on opportunities for growth, and we also funded a new middle market investment in the first quarter. As of March 31, we had $10.9 million in commitments to fund investments under various credit facilities to our portfolio companies. The majority of our investments are in loans and approximately 100% of our loan portfolio at fair value was senior secured as of March 31. Based on amortized cost as of quarter end, our investment portfolio was comprised of approximately 69% senior secured loans, 1% subordinated debt, 24% structured finance securities and 6% equity securities. At the end of the quarter, we had investments in 74 unique issuers totaling $400.4 million on a fair value basis. The weighted average performing investment income yield on the interest-bearing portion of the portfolio was 13%, which is down about 1.1% quarter-over-quarter. This includes all interest, prepayment fees and amortization of deferred loan fees. The decline was largely due to the nonaccrual loan I mentioned earlier as well as a slight decrease on the yields earned on our structured finance investments. With that, I'll turn the call back over to Bilal.